Cantel Medical (CMD)
Overall CMD gets a fundamental rating of 3 out of 10. We evaluated CMD against 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CMD have multiple concerns. While showing a medium growth rate, CMD is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CMD was profitable.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 6.37% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.54% | ||
| PM (TTM) | 4.57% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 2.98 indicates that CMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
A Debt/Equity ratio of 0.90 indicates that CMD is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.98 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
CMD has a Current Ratio of 2.58. This indicates that CMD is financially healthy and has no problem in meeting its short term obligations.
CMD has a Quick Ratio of 1.84. This is a normal value and indicates that CMD is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 1.84 |
3. Growth
3.1 Past
The earnings per share for CMD have decreased strongly by -29.96% in the last year.
The Earnings Per Share has been growing by 25.92% on average over the past years. This is a very strong growth
The Revenue has grown by 11.37% in the past year. This is quite good.
Measured over the past years, CMD shows a quite strong growth in Revenue. The Revenue has been growing by 12.45% on average per year.
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y25.92%
EPS growth Q2Q27.03%
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y12.45%
Revenue growth Q2Q32.51%
3.2 Future
CMD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.07% yearly.
The Revenue is expected to grow by 8.80% on average over the next years. This is quite good.
EPS Next Y82.92%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
EPS Next 5Y21.07%
Revenue Next Year17.48%
Revenue Next 2Y11.96%
Revenue Next 3Y10.48%
Revenue Next 5Y8.8%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
CMD is valuated quite expensively with a Price/Earnings ratio of 48.42.
CMD's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.28.
The Price/Forward Earnings ratio is 25.61, which means the current valuation is very expensive for CMD.
CMD is valuated rather expensively when we compare the Price/Forward Earnings ratio to 20.88, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.42 | ||
| Fwd PE | 25.61 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 19.45 |
4.3 Compensation for Growth
CMD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as CMD's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)0.58
PEG (5Y)1.87
EPS Next 2Y37.5%
EPS Next 3Y29.83%
5. Dividend
5.1 Amount
CMD has a yearly dividend return of 0.13%, which is pretty low.
Compared to an average S&P500 Dividend Yield of 2.41, CMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.13% |
5.2 History
On average, the dividend of CMD grows each year by 25.79%, which is quite nice.
CMD has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)25.79%
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
The dividend of CMD is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP0%
EPS Next 2Y37.5%
EPS Next 3Y29.83%
Cantel Medical
NYSEARCA:CMD (6/1/2021, 7:24:59 PM)
After market: 80.37 0 (0%)80.37
-0.96 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.58B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.13% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.42 | ||
| Fwd PE | 25.61 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.58
PEG (5Y)1.87
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.56% | ||
| ROE | 6.37% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 11.54% | ||
| PM (TTM) | 4.57% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.58 | ||
| Quick Ratio | 1.84 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-29.96%
EPS 3Y-4.57%
EPS 5Y
EPS growth Q2Q
EPS Next Y82.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)11.37%
Revenue growth 3Y9.68%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y